Medtecs International Issues Key Update on Resilient Medical Liquidation

Introduction

Medtecs International Corporation Limited (“Medtecs” or the “Company”) has released its latest monthly update concerning the ongoing liquidation proceedings of its subsidiary, Resilient Medical. This development follows a series of previous announcements and forms part of the company’s obligation to update shareholders under Catalist Rule 704(22).

Key Developments

• Liquidation Application Filed: The appointed liquidator has officially filed the relevant application regarding the liquidation of Resilient Medical with the High Court of Singapore on 22 January 2026.
• Court Hearing Date Set: The hearing for the application is scheduled for 3 February 2026 at 10:00 a.m. The Group is currently awaiting the outcome of this hearing and the issuance of the final court order, which will determine the future of Resilient Medical.
• Previous Announcements: This update is part of a series of disclosures made throughout 2024 and 2025, indicating the company’s commitment to keeping shareholders informed of significant events.

Financial Impact and Implications for Shareholders

• No Material Impact Expected: Based on the information available, the Board has assessed that the winding-up of Resilient Medical and the dividend in specie (the transfer of the entire issued share capital in RMKH SG to the Company) will not have a material impact on Medtecs’ net tangible assets per share or earnings per share for the financial year ending 31 December 2026.
• Ongoing Updates: The Company has committed to releasing further announcements as and when there are material developments in relation to the liquidation proceedings, in addition to the monthly updates.

Important Considerations for Investors

• Price Sensitivity: While the Board does not expect any material financial impact at this stage, the outcome of the court hearing could introduce new developments. Investors should remain alert to further announcements, as any changes in the status or outcome of the liquidation could potentially affect the Company’s share price.
• Caution Advised: Shareholders and potential investors are strongly advised to refrain from taking any action regarding their securities that may be prejudicial to their interests. Exercising caution when dealing in the Company’s shares is recommended until the final court order is issued and further clarity on the situation is provided.
• Professional Advice: Investors uncertain about how these developments may affect their holdings should consult with stockbrokers, bank managers, solicitors, or other professional advisers.

Corporate Governance and Compliance

• Board Oversight: The announcement is made under the authority of Clement Yang Ker-Cheng, Chairman and Executive Director, ensuring high-level oversight and transparency for all stakeholders.
• Sponsor Review: The Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd., has reviewed the announcement, although the Singapore Exchange Securities Trading Limited has not examined or approved its contents.

Conclusion

Medtecs International continues to demonstrate transparency and diligence in keeping shareholders informed of the Resilient Medical liquidation process. While no immediate material financial impact is anticipated, investors should monitor upcoming announcements closely, especially following the court hearing on 3 February 2026, as the final outcome could shape the Group’s future structure and potentially impact share valuations.

Disclaimer: This article is a summary and interpretation of Medtecs International’s official announcement regarding the liquidation of Resilient Medical. It does not constitute investment advice. Investors are encouraged to consult their professional advisers before making any investment decisions based on this information.

View Medtecs Intl Historical chart here